Program
P134
A development code. Also written as “P134 cell injection”.
Its studies are mostly in Glioblastoma, led by China Resources Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| China Resources Pharmaceutical Group | 11 open or running | phase 2since Nov 27, 2025 | Nov 27, 2025 | Feb 29, 2028phase 2 · NCT07318818 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 27, 2025First study: phase 2 study in Recurrent Glioblastoma IDH WildtypeFirst studyNCT07318818 · 26 planned · China
Ahead
- Feb 29, 2028Primary completion: phase 2 study in Recurrent Glioblastoma IDH WildtypeNCT07318818
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07318818Recurrent Glioblastoma IDH Wildtype · China | 2 | Recruiting | Feb 29, 2028 | 26 |
How it is read
Names in the registry
- “P134 cell injection”, 1 entry
Codes read as this program: P134.
Conditions, from the studies’ own filings
- Glioblastoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.